Talk to our Consultant - Saudi Arabia Diabetes Drug Market Size, Share & Trend 2026-2032

Saudi Arabia Diabetes Drug Market Research Report: Forecast (2026-2032)

Saudi Arabia Diabetes Drug Market - By Insulins (Basal [Lantus {Insulin Glargine}, Levemir {Insulin Detemir}, Toujeo{Insulin Glargine}, Tresiba{Insulin Degludec}, Basaglar {Insulin Glargine}], Bolous... ... Glargine}], Bolous [NovoRapid/Novolog {Insulin Aspart}, Humalog {Insulin Lispro}, Apidra {Insulin Glulisine}], Traditional Insulins [Novolin/ Actrapid/Insulatard, Humulin, Insuman], Biosimilar Insulins [Insulin Glargine Biosimilars, Human Insulin Biosimilars)], By Oral Anti-Diabetic Drugs (Biguanides [Metformin], Alpha-Glucosidase Inhibitors, Dopamine D2 receptor agonist [Bromocriptin], SGLT-2 Inhibitors [Invokana {Canagliflozin}, Jardiance {Empagliflozin}, Farxiga/Forxiga {Dapagliflozin}, Suglat {Ipragliflozin}], DPP-4 Inhibitors [Onglyza {Saxagliptin}, Tradjenta {Linagliptin}, Vipidia/Nesina{Alogliptin}, Galvus {Vildagliptin}], Sulfonylureas, Meglitinides), By Non-Insulin Injection Drugs (GLP-1 Receptor Agonists [Victoza {Liraglutide}, Byetta {Exenatide}, Bydureon {Exenatide}, Trulicity {Dulaglutide}, Lyxumia {Lixisenatide}], Amylin Analogue [Symlin {Pramlintide}]), By Combination Drugs (Insulin Combinations [NovoMix {Biphasic Insulin Aspart}, Ryzodeg {Insulin Degludec and Insulin Aspart}, Xultophy {Insulin Degludec and Liraglutide}], Oral Combinations [Janumet {Sitagliptin and Metformin}]), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics and Diabetes Centers) and Others Read more

Healthcare
Jan 2026
Pages 135
Report Format: PDF, Excel, PPT

Market Definition

Diabetic drugs aid individuals afflicted with the disease to maintain their blood glucose levels. They cannot heal the patient but they reduce the likelihood of complications.

Market Insights & Analysis: Saudi Arabia Diabetes Drug Market (2026-2032):

The Saudi Arabia Diabetes Drug Market size was valued at around USD 499 million in 2025 and is projected to reach USD 740.2 million by 2032. Along with this, the market is estimated to grow at a CAGR of around 6.79% during the forecast period, i.e., 2026-32. The rate of diabetes is intensively increasing in the region which is creating the demand for the drugs. Also, the increasing spending on the healthcare system with government programs and support is further driving the demand for Diabetes drugs in Saudi Arabia. The government has also been focusing on providing insurance coverage for diseases and the incorporation of new technologies for cutting-edge treatment options for diabetes.

The youth in the region are at a higher risk for developing the disease currently leading to the increase in healthcare costs, adverse quality of life coupled with shorter life expectancy. The Saudi Arabian region is suffering from diabetes intensively as in about 10 people more than 1 is suffering from the disease and the ubiquity of the disease will almost double by 2045. Also, the report by the IDF indicates that around 1.86 million citizens in Saudi Arabia have diabetes but still not recognized yet. Currently, 4.27 million Saudi Arabian people have diabetes. This number is expected to grow to 5.6 million by 2030 and can reach 7.5 million by 2045. The ubiquity of diabetes is increasing in Saudi Arabia with unhealthy lifestyles and an increasingly obese population, ultimately creating a heavy demand for the Saudi Arabia Diabetes Drug Market.

By 2030, a 10% reduction is planned by Saudi Arabia in the ubiquity of diabetes. Moreover, they have provided multiple investments for diabetes drugs to promote market growth. For instance; Saudia Arabia provided 25-35% of their healthcare budget for various diseases like obesity and diabetes. It also included cardiovascular diseases caused due to adverse diabetes in the region. Other government initiatives include high taxation on sugary drinks and a focus on preventive diabetes care coupled with fitness programs. They imposed a 50% tax on various beverages containing high sugar, in the past few years. In addition to this, a 100% tax was also imposed on energy drinks. Combating diabetes by the government, along with the higher purchasing power of the people in the country, may help the market for diabetes drugs during the forecast period.

Saudi Arabia Diabetes Drug Market Scope:

Category	Segments
By Insulins	Basal [Lantus {Insulin Glargine}, Levemir {Insulin Detemir}, Toujeo{Insulin Glargine}, Tresiba{Insulin Degludec}, Basaglar {Insulin Glargine}], Bolous [NovoRapid/Novolog {Insulin Aspart}, Humalog {Insulin Lispro}, Apidra {Insulin Glulisine}], Traditional Insulins [Novolin/ Actrapid/Insulatard, Humulin, Insuman], Biosimilar Insulins [Insulin Glargine Biosimilars, Human Insulin Biosimilars)],
By Oral Anti-Diabetic Drugs	Biguanides [Metformin], Alpha-Glucosidase Inhibitors, Dopamine D2 receptor agonist [Bromocriptin], SGLT-2 Inhibitors [Invokana {Canagliflozin}, Jardiance {Empagliflozin}, Farxiga/Forxiga {Dapagliflozin}, Suglat {Ipragliflozin}], DPP-4 Inhibitors [Onglyza {Saxagliptin}, Tradjenta {Linagliptin}, Vipidia/Nesina{Alogliptin}, Galvus {Vildagliptin}], Sulfonylureas, Meglitinides),
By Non-Insulin Injection Drugs	GLP-1 Receptor Agonists [Victoza {Liraglutide}, Byetta {Exenatide}, Bydureon {Exenatide}, Trulicity {Dulaglutide}, Lyxumia {Lixisenatide}], Amylin Analogue [Symlin {Pramlintide}]),
By Combination Drugs	Insulin Combinations [NovoMix {Biphasic Insulin Aspart}, Ryzodeg {Insulin Degludec and Insulin Aspart}, Xultophy {Insulin Degludec and Liraglutide}], Oral Combinations [Janumet {Sitagliptin and Metformin}]),
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics and Diabetes Centers) and Others

Saudi Arabia Diabetes Drug Market Driver:

High Prevalence of Diabetes Propelling Market Growth

Due to genetic predispositions and unhealthy lifestyle choices, Saudi Arabia has one of the highest prevalence rates in the world. By 2026, around 24% of the total adult population of Saudi Arabia is expected to have Diabetes which was just around 17.7% in 2021. This rising prevalence is leading the nation to become the 2nd highest in the Middle East and 7th highest globally in diabetes occupancy. An unhealthy lifestyle has resulted in the prevalence of obesity-related problems in Saudi Arabia that majorly pose a threat to several chronic diseases like Type-2 diabetes. An approximate 35.4% of the adult population of Saudi Arabia suffers from obesity. This creates an immense nationwide demand for Diabetes Drugs for the treatment and prevention of diabetes, thereby significantly contributing to the market growth.

Another reason is the country has some of the highest per capita consumption of sugar-filled drinks which worsens the diabetes epidemic. High prevalence rates of the disease result from this sort of sedentary behavior allied with diets full of fat and sugar which fuels the growth of the Saudi Arabia Diabetes Drug Market.

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
Saudi Arabia Diabetes Drug Market Trends & Deployments
Saudi Arabia Diabetes Drug Market Dynamics
1. Growth Drivers
2. Challenges
Saudi Arabia Diabetes Drug Market Opportunities & Hotspots
Saudi Arabia Diabetes Drug Market Value Chain Analysis
Saudi Arabia Diabetes Drug Market Regulations and Policy
Saudi Arabia Diabetes Drug Market Outlook, 2022-2032
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Segmentation & Analysis
  1. By Insulins
    1. Basal- Market Size & Forecast 2022-2032, USD Million
      1. Lantus (Insulin Glargine)- Market Size & Forecast 2022-2032, USD Million
      2. Levemir (Insulin Detemir)- Market Size & Forecast 2022-2032, USD Million
      3. Toujeo(Insulin Glargine)- Market Size & Forecast 2022-2032, USD Million
      4. Tresiba(Insulin Degludec)- Market Size & Forecast 2022-2032, USD Million
      5. Basaglar (Insulin Glargine) - Market Size & Forecast 2022-2032, USD Million
    2. Bolous- Market Size & Forecast 2022-2032, USD Million
      1. NovoRapid/Novolog (Insulin Aspart)- Market Size & Forecast 2022-2032, USD Million
      2. Humalog (Insulin Lispro)- Market Size & Forecast 2022-2032, USD Million
      3. Apidra (Insulin Glulisine)- Market Size & Forecast 2022-2032, USD Million
    3. Traditional Insulins- Market Size & Forecast 2022-2032, USD Million
      1. Novolin/ Actrapid/Insulatard- Market Size & Forecast 2022-2032, USD Million
      2. Humulin- Market Size & Forecast 2022-2032, USD Million
      3. Insuman- Market Size & Forecast 2022-2032, USD Million
    4. Biosimilar Insulins- Market Size & Forecast 2022-2032, USD Million
      1. Insulin Glargine Biosimilars- Market Size & Forecast 2022-2032, USD Million
      2. Human Insulin Biosimilars- Market Size & Forecast 2022-2032, USD Million
  2. By Oral Anti-Diabetic Drugs
    1. Biguanides- Market Size & Forecast 2022-2032, USD Million
      1. Metformin- Market Size & Forecast 2022-2032, USD Million
    2. Alpha-Glucosidase Inhibitors- Market Size & Forecast 2022-2032, USD Million
    3. Dopamine D2 receptor agonist- Market Size & Forecast 2022-2032, USD Million
      1. Bromocriptin- Market Size & Forecast 2022-2032, USD Million
    4. SGLT-2 Inhibitors- Market Size & Forecast 2022-2032, USD Million
      1. Invokana (Canagliflozin)- Market Size & Forecast 2022-2032, USD Million
      2. Jardiance (Empagliflozin)- Market Size & Forecast 2022-2032, USD Million
      3. Farxiga/Forxiga (Dapagliflozin)- Market Size & Forecast 2022-2032, USD Million
      4. Suglat (Ipragliflozin)- Market Size & Forecast 2022-2032, USD Million
    5. DPP-4 Inhibitors- Market Size & Forecast 2022-2032, USD Million
      1. Onglyza (Saxagliptin)- Market Size & Forecast 2022-2032, USD Million
      2. Tradjenta (Linagliptin)- Market Size & Forecast 2022-2032, USD Million
      3. Vipidia/Nesina(Alogliptin)- Market Size & Forecast 2022-2032, USD Million
      4. Galvus (Vildagliptin)- Market Size & Forecast 2022-2032, USD Million
    6. Sulfonylureas- Market Size & Forecast 2022-2032, USD Million
    7. Meglitinides- Market Size & Forecast 2022-2032, USD Million
  3. By Non-Insulin Injection Drugs
    1. GLP-1 Receptor Agonists- Market Size & Forecast 2022-2032, USD Million
      1. Victoza (Liraglutide)- Market Size & Forecast 2022-2032, USD Million
      2. Byetta (Exenatide)- Market Size & Forecast 2022-2032, USD Million
      3. Bydureon (Exenatide)- Market Size & Forecast 2022-2032, USD Million
      4. Trulicity (Dulaglutide)- Market Size & Forecast 2022-2032, USD Million
      5. Lyxumia (Lixisenatide)- Market Size & Forecast 2022-2032, USD Million
    2. Amylin Analogue- Market Size & Forecast 2022-2032, USD Million
      1. Symlin (Pramlintide)- Market Size & Forecast 2022-2032, USD Million
  4. By Combination Drugs
    1. Insulin Combinations- Market Size & Forecast 2022-2032, USD Million
      1. NovoMix (Biphasic Insulin Aspart)- Market Size & Forecast 2022-2032, USD Million
      2. Ryzodeg (Insulin Degludec and Insulin Aspart)- Market Size & Forecast 2022-2032, USD Million
      3. Xultophy (Insulin Degludec and Liraglutide)- Market Size & Forecast 2022-2032, USD Million
    2. Oral Combinations- Market Size & Forecast 2022-2032, USD Million
      1. Janumet (Sitagliptin and Metformin)- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel
    1. Hospital Pharmacies- Market Size & Forecast 2022-2032, USD Million
    2. Retail Pharmacies- Market Size & Forecast 2022-2032, USD Million
    3. Online Pharmacies- Market Size & Forecast 2022-2032, USD Million
    4. Clinics and Diabetes Centers- Market Size & Forecast 2022-2032, USD Million
  6. By Region
    1. Northern
    2. Central
    3. Southern
    4. Eastern
    5. Western
  7. By Company
    1. Competition Characteristics
    2. Market Share and Analysis
Northern Saudi Arabia Diabetes Drug Market Outlook, 2022-2032
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Segmentation & Analysis
  1. By Insulin- Market Size & Forecast 2022-2032, USD Million
  2. By Oral Anti-Diabetic Drugs-Market Size & Forecast 2022-2032, USD Million
  3. By Non-Insulin Injection Drugs- Market Size & Forecast 2022-2032, USD Million
  4. By Combination Drugs-Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
Southern Saudi Arabia Diabetes Drug Market Outlook, 2022-2032
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Segmentation & Analysis
  1. By Insulin- Market Size & Forecast 2022-2032, USD Million
  2. By Oral Anti-Diabetic Drugs-Market Size & Forecast 2022-2032, USD Million
  3. By Non-Insulin Injection Drugs- Market Size & Forecast 2022-2032, USD Million
  4. By Combination Drugs-Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
Central Saudi Arabia Diabetes Drug Market Outlook, 2022-2032
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Segmentation & Analysis
  1. By Insulin- Market Size & Forecast 2022-2032, USD Million
  2. By Oral Anti-Diabetic Drugs-Market Size & Forecast 2022-2032, USD Million
  3. By Non-Insulin Injection Drugs- Market Size & Forecast 2022-2032, USD Million
  4. By Combination Drugs-Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
Eastern Saudi Arabia Diabetes Drug Market Outlook, 2022-2032
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Segmentation & Analysis
  1. By Insulin- Market Size & Forecast 2022-2032, USD Million
  2. By Oral Anti-Diabetic Drugs-Market Size & Forecast 2022-2032, USD Million
  3. By Non-Insulin Injection Drugs- Market Size & Forecast 2022-2032, USD Million
  4. By Combination Drugs-Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
Western Saudi Arabia Diabetes Drug Market Outlook, 2022-2032
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Segmentation & Analysis
  1. By Insulin- Market Size & Forecast 2022-2032, USD Million
  2. By Oral Anti-Diabetic Drugs-Market Size & Forecast 2022-2032, USD Million
  3. By Non-Insulin Injection Drugs- Market Size & Forecast 2022-2032, USD Million
  4. By Combination Drugs-Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
Saudi Arabia Diabetes Drug Market Strategic Imperatives for Growth & Success
Competition Outlook
1. Company Profiles
  1. Novo Nordisk A/S
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  2. Takeda
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  3. Pfizer
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  4. Eli Lilly
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  5. Janssen Pharmaceuticals
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  6. Astellas
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  7. Boehringer Ingelheim
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  8. Merck and Co.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  9. AstraZeneca
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  10. Julphar
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  11. Bristol Myers Squibb
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  12. Novartis
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  13. Sanofi Aventis
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Deployments
    5. Financial Details
    6. Others
  14. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Full Name*:

Company Name*:

Business Email*:

Country Name*:

Contact Number*:

Message:

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Inquire Before Buying